PER 1.41% 7.0¢ percheron therapeutics limited

Ann: Share Purchase Plan Closes , page-33

  1. 14,981 Posts.
    lightbulb Created with Sketch. 51
    peace, maybe revenue might fall in line with your thoughts, but:
    "Clinical Trials -

    Double cost estimates & extend time frames by 12 months"

    I'll put money on that not happening
    ANP has always delivered under budget and on time or before in the past, and I expect that to remain the case

    However, as you said, yes it's all speculation, as is the broad generalisation from a biotech analyst
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.